Pharmaceutical composition for irritable bowel syndrome containing quinolone compound
CN119343138APending Publication Date: 2025-01-21OTSUKA PHARM CO LTD
Patent Information
- Application Number
- CN202380048648.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-11
- Filing Date
- 2023-07-11
- Publication Date
- 2025-01-21
AI Technical Summary
Technical Problem
[0003]目前还没有治愈IBS的方法
Benefits of technology
[0006] The main purpose of the present invention is to provide a new drug for the treatment and/or prevention of irritable bowel syndrome (IBS), especially IBS-D, which is more effective than existing drugs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN119343138A_ABST
Abstract
The invention relates to a pharmaceutical composition containing a quinolone compound for irritable bowel syndrome, in particular to the quinolone compound, especially 1-cyclopropyl-6-fluoro-1, 3, 4-oxadiazole. The invention relates to a use of 2, 4-dihydro-8-methyl-7-(2-amino-3-cyano-5-pyridyl)-4-oxo-3-quinoline-formic acid or a pharmacologically acceptable salt, hydrate, solvate or deuteride thereof in the prevention or treatment of irritable bowel syndrome in humans or animals.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Quinolone compound
WO2013029548A1